News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2020 Shelley Wood October 01, 2020
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds Michael O'Riordan August 13, 2020
News Daily News FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction Shelley Wood May 06, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Daily News VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint Todd Neale November 20, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
Presentation TCT 2019 Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial Presenter: Felix Mahfoud September 27, 2019
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Conference News ESC 2019 Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients Todd Neale September 13, 2019
News Conference News ESC 2019 Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis Yael L. Maxwell September 12, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019